Published in Surgery on December 01, 2005
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg (2008) 1.39
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
Notch signaling in lung cancer. Expert Rev Anticancer Ther (2011) 1.00
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol (2008) 0.98
Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery (2007) 0.95
Expression of the active Notch1 decreases MTC tumor growth in vivo. J Surg Res (2011) 0.91
Lithium inhibits carcinoid cell growth in vitro. Am J Transl Res (2010) 0.87
The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study. J Cancer Res Clin Oncol (2009) 0.86
Lentivirus-mediated RNA interference targeting the H19 gene inhibits cell proliferation and apoptosis in human choriocarcinoma cell line JAR. BMC Cell Biol (2013) 0.86
Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion. Am J Surg (2007) 0.84
Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer. Ann Surg Oncol (2014) 0.82
Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo. Cancer Gene Ther (2014) 0.80
Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line. Cancer Med (2013) 0.80
Goblet cell carcinoids of the appendix: Tumor biology, mutations and management strategies. World J Gastrointest Surg (2016) 0.79
Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells. Transl Oncogenomics (2007) 0.79
The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors. Glob J Biochem (2011) 0.78
Notch Signaling in Neuroendocrine Tumors. Front Oncol (2016) 0.78
Notch-1 and Ki-67 receptor as predictors for the recurrence and prognosis of Kimura's disease. Int J Clin Exp Pathol (2014) 0.77
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist (2016) 0.76
Targeting the Notch signaling pathway in cancer therapeutics. Thorac Cancer (2014) 0.75
Notch as a tumour suppressor. Nat Rev Cancer (2017) 0.75
Carcinoid tumors. Oncologist (2008) 2.86
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab (2007) 2.26
Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg (2013) 2.10
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg (2013) 1.96
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid (2013) 1.77
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg (2010) 1.71
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg (2011) 1.64
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol (2007) 1.56
Remnant uptake as a postoperative oncologic quality indicator. Thyroid (2013) 1.56
The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol (2004) 1.53
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 1.53
25-hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol (2010) 1.50
Can thallium-pertechnetate subtraction scanning play a role in the preoperative imaging for minimally invasive parathyroidectomy? Clin Nucl Med (2004) 1.47
Radioguided parathyroidectomy in patients with familial hyperparathyroidism. Ann Surg Oncol (2006) 1.46
Thyroidectomy decreases snoring and sleep apnea symptoms. Thyroid (2012) 1.46
Carcinoid tumors. Surg Oncol Clin N Am (2006) 1.45
Pancreatic endocrine tumors. J Surg Res (2004) 1.42
Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes. Surgery (2009) 1.42
The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. World J Surg (2011) 1.42
Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males. J Surg Res (2009) 1.42
All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. Ann Surg Oncol (2014) 1.41
How Well Does Renal Transplantation Cure Hyperparathyroidism? Ann Surg (2015) 1.40
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg (2008) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery (2006) 1.34
Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am (2009) 1.34
Treatment of advanced carcinoid tumors. Curr Opin Oncol (2006) 1.32
Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) (2008) 1.31
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Surgery for primary hyperparathyroidism: what is the best approach? Ann Surg (2002) 1.26
Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg (2006) 1.22
Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: the surgical approach of choice for patients with mediastinal parathyroid adenomas? J Bone Miner Res (2002) 1.22
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 1.21
What is the clinical significance of an elevated parathyroid hormone level after curative surgery for primary hyperparathyroidism? Ann Surg (2009) 1.20
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 1.19
Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg (2004) 1.18
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 1.17
Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg (2009) 1.17
Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery (2012) 1.17
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
Medical student operative experience correlates with a match to a categorical surgical program. Am J Surg (2003) 1.15
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer (2010) 1.15
Total thyroidectomy: a safe and effective treatment for Graves' disease. J Surg Res (2011) 1.15
Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol (2012) 1.14
Contralateral papillary thyroid cancer: does size matter? Am J Surg (2009) 1.14
Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery (2010) 1.14
Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism. Surgery (2003) 1.12
Why do students choose careers in surgery? J Surg Res (2004) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol (2012) 1.10
Parathyroid hormone deficiency after total thyroidectomy: incidence and time. J Surg Res (2010) 1.10
Calciphylaxis in the absence of end-stage renal disease. Endocr Pract (2006) 1.09
New trends in parathyroid surgery. Curr Probl Surg (2010) 1.09
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 1.09
The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res (2007) 1.08
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid (2011) 1.08
Creation of a "Wisconsin index" nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg (2013) 1.07
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Curr Opin Investig Drugs (2008) 1.06
In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs (2006) 1.06
Radioguided parathyroidectomy for recurrent hyperparathyroidism caused by forearm graft hyperplasia. J Bone Miner Res (2003) 1.06
Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol (2008) 1.06
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther (2009) 1.05
Thyroid hormone replacement after thyroid lobectomy. Surgery (2009) 1.05
Palliation of advanced thyroid malignancies. Surg Oncol (2007) 1.05
Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res (2009) 1.04
Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol (2014) 1.04
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res (2006) 1.04
Are there predictors of malignancy in patients with multinodular goiter? J Surg Res (2011) 1.03
The surgical management of Graves' disease. J Surg Res (2006) 1.03
Fine-needle aspiration optimizes surgical management in patients with thyroid cancer. Ann Surg Oncol (2006) 1.02
What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J Surg Res (2006) 1.02
The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg (2007) 1.01
ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res (2006) 1.01
Predictors of recurrence in primary hyperparathyroidism: an analysis of 1386 cases. Ann Surg (2014) 1.01
Advances in surgical therapy for thyroid cancer. Nat Rev Endocrinol (2011) 1.01
Effective surgical residents strongly influence medical students to pursue surgical careers. J Am Coll Surg (2007) 1.01
Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther (2013) 1.01
Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid (2009) 1.01
What is the optimal treatment for children with primary hyperparathyroidism? J Pediatr Surg (2010) 1.00
Same-day thyroidectomy program: eligibility and safety evaluation. Surgery (2012) 1.00
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg (2009) 1.00
Risks and consequences of incidental parathyroidectomy during thyroid resection. ANZ J Surg (2007) 1.00
A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery (2013) 0.99
Current understanding and management of medullary thyroid cancer. Oncologist (2013) 0.99